ENvue Medical Inc. (FEED) - Net Assets
Based on the latest financial reports, ENvue Medical Inc. (FEED) has net assets worth $32.02 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.87 Million) and total liabilities ($7.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ENvue Medical Inc. (FEED) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.02 Million |
| % of Total Assets | 80.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | 430.6% |
| 10-Year Change | N/A |
| Growth Volatility | 1725.51 |
ENvue Medical Inc. - Net Assets Trend (2011–2025)
This chart illustrates how ENvue Medical Inc.'s net assets have evolved over time, based on quarterly financial data. See ENvue Medical Inc. (FEED) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for ENvue Medical Inc. (2011–2025)
The table below shows the annual net assets of ENvue Medical Inc. from 2011 to 2025. For live market cap and overall valuation, see how much is ENvue Medical Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $33.50 Million | +5242.42% |
| 2024-12-31 | $627.00K | -84.28% |
| 2023-12-31 | $3.99 Million | +23.35% |
| 2022-12-31 | $3.23 Million | -48.79% |
| 2021-12-31 | $6.31 Million | +163.70% |
| 2020-12-31 | $2.39 Million | +77.60% |
| 2019-12-31 | $1.35 Million | +191.14% |
| 2018-12-31 | $463.00K | -87.26% |
| 2017-12-31 | $3.63 Million | +245.42% |
| 2016-12-31 | $-2.50 Million | -1095.69% |
| 2015-12-31 | $-209.00K | +96.28% |
| 2014-12-31 | $-5.62 Million | -70.34% |
| 2013-12-31 | $-3.30 Million | -79.97% |
| 2012-12-31 | $-1.83 Million | -213.16% |
| 2011-12-31 | $-585.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ENvue Medical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7954200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $-80.00K | -0.24% |
| Other Components | $124.06 Million | 370.35% |
| Total Equity | $33.50 Million | 100.00% |
ENvue Medical Inc. Competitors by Market Cap
The table below lists competitors of ENvue Medical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
APC Minerals Ltd
AU:APC
|
$3.64 Million |
|
Tissue Repair Ltd
AU:TRP
|
$3.64 Million |
|
Indus Gas Ltd
F:59Q
|
$3.64 Million |
|
Parx Plastics NV
PA:MLPRX
|
$3.65 Million |
|
NOROO Paint & Coatings Co Ltd
KO:090355
|
$3.63 Million |
|
Tersis Technologies Inc.
NASDAQ:TERS
|
$3.63 Million |
|
City Office
NYSE:CIO
|
$3.63 Million |
|
Telo Genomics Corp
V:TELO
|
$3.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENvue Medical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 627,000 to 33,497,000, a change of 32,870,000 (5242.4%).
- Net loss of 18,185,000 reduced equity.
- Share repurchases of 5,000,000 reduced equity.
- New share issuances of 19,089,000 increased equity.
- Other factors increased equity by 36,966,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.18 Million | -54.29% |
| Share Repurchases | $5.00 Million | -14.93% |
| Share Issuances | $19.09 Million | +56.99% |
| Other Changes | $36.97 Million | +110.36% |
| Total Change | $- | 5242.42% |
Book Value vs Market Value Analysis
This analysis compares ENvue Medical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-282.20 | $0.39 | x |
| 2012-12-31 | $-883.74 | $0.39 | x |
| 2013-12-31 | $-1590.45 | $0.39 | x |
| 2014-12-31 | $-2709.12 | $0.39 | x |
| 2015-12-31 | $-232.41 | $0.39 | x |
| 2016-12-31 | $-1200.86 | $0.39 | x |
| 2017-12-31 | $1610.82 | $0.39 | x |
| 2018-12-31 | $157.97 | $0.39 | x |
| 2019-12-31 | $427.39 | $0.39 | x |
| 2020-12-31 | $511.54 | $0.39 | x |
| 2021-12-31 | $551.98 | $0.39 | x |
| 2022-12-31 | $250.50 | $0.39 | x |
| 2023-12-31 | $250.66 | $0.39 | x |
| 2024-12-31 | $23.24 | $0.39 | x |
| 2025-12-31 | $39.02 | $0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ENvue Medical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -712.30%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.23x
- Recent ROE (-54.29%) is above the historical average (-186.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -769.15% | 0.09x | 0.00x | $-664.50K |
| 2012 | 0.00% | -768.07% | 0.48x | 0.00x | $-1.09 Million |
| 2013 | 0.00% | -942.65% | 0.31x | 0.00x | $-1.66 Million |
| 2014 | 0.00% | -1303.94% | 0.28x | 0.00x | $-2.09 Million |
| 2015 | 0.00% | -1961.90% | 0.07x | 0.00x | $-2.86 Million |
| 2016 | 0.00% | -1236.24% | 0.46x | 0.00x | $-2.58 Million |
| 2017 | -159.77% | -2429.29% | 0.05x | 1.34x | $-6.17 Million |
| 2018 | -897.19% | -1306.29% | 0.20x | 3.41x | $-4.20 Million |
| 2019 | -429.82% | -1093.21% | 0.26x | 1.51x | $-5.93 Million |
| 2020 | -180.66% | -694.22% | 0.08x | 3.44x | $-4.56 Million |
| 2021 | -226.23% | -842.60% | 0.20x | 1.37x | $-14.91 Million |
| 2022 | -168.51% | -724.47% | 0.13x | 1.82x | $-5.77 Million |
| 2023 | -93.05% | -162.55% | 0.34x | 1.67x | $-4.11 Million |
| 2024 | -590.91% | -144.84% | 0.70x | 5.79x | $-3.77 Million |
| 2025 | -54.29% | -712.30% | 0.06x | 1.23x | $-21.53 Million |
Industry Comparison
This section compares ENvue Medical Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $950,974,451
- Average return on equity (ROE) among peers: -69.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENvue Medical Inc. (FEED) | $32.02 Million | 0.00% | 0.25x | $3.63 Million |
| Abbott Laboratories (ABT) | $7.43 Billion | 32.93% | 0.95x | $196.11 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $14.41 Million |
| Aethlon Medical Inc (AEMD) | $5.77 Million | -211.71% | 0.43x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $762.44 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $5.69 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $2.07 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $2.86 Million |
| Artivion Inc (AORT) | $24.90 Million | 15.66% | 0.41x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $131.43 Million |
About ENvue Medical Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, incre… Read more